Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ET-743 (PharmaMar/NCI/Ortho Biotech).

C F Verschraegen1, K Glover

  • 1University of Texas, MD Anderson Cancer Center, Houston 77030, USA. cverschr@mail.mdanderson.org

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interdependence of Cultivar and Environment on Fiber Composition in Wheat Bran.

Australian journal of crop science·2018
Same author

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Investigational new drugs·2008
Same author

Absence of epidermal growth factor receptor mutations in cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
Same author

Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Journal of cancer research and clinical oncology·2003

Ecteinascidin-743 (ET-743), a novel cancer therapeutic, is under development for various tumors. This DNA-targeting agent has shown promise in clinical trials, leading to Orphan Drug status for soft tissue sarcoma.

Area of Science:

  • Pharmacology and Oncology
  • Drug Development
  • Marine Biotechnology

Background:

  • Ecteinascidin-743 (ET-743) is a potent anti-cancer compound derived from the marine tunicate Ecteinascidia turbinata.
  • ET-743 functions by alkylating DNA's minor groove, leading to DNA strand breaks mediated by topoisomerase I.
  • It is an analog of the previously studied compound ET-729.

Purpose of the Study:

  • To evaluate the potential of ET-743 as a treatment for various cancer types.
  • To assess the clinical development status and regulatory progress of ET-743.
  • To understand the commercial projections and market potential for ET-743.

Main Methods:

  • Clinical trials (Phase II) were conducted to assess efficacy and safety in patients with breast cancer, ovarian cancer, lung cancer, and melanoma.

Related Experiment Videos

  • Regulatory submissions and reviews by agencies like the European Medicines Agency (EMEA) were undertaken.
  • Market analysis and sales forecasts were performed by financial institutions.

    • Main Results:

    • ET-743 demonstrated potential in treating multiple tumor types, including breast, ovarian, lung cancers, and melanoma.
    • Orphan Drug status was granted by the EMEA for the treatment of soft tissue sarcoma, indicating unmet medical need.
    • Significant sales projections were made, indicating strong commercial expectations for ET-743.

    Conclusions:

    • ET-743 is a promising anti-cancer drug candidate with a unique mechanism of action.
    • Its development is progressing through clinical trials, with regulatory milestones achieved.
    • ET-743 represents a significant potential therapeutic and commercial asset in oncology.